Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/24/2025

Management of Inflammatory Bowel Disease with Elevated Fecal Calprotectin

Assessment and Treatment Approach

  • For patients with moderate to severe symptoms and fecal calprotectin >150 μg/g, treatment adjustment is warranted without requiring immediate endoscopic assessment, as suggested by the American Gastroenterological Association (AGA) 1
  • The AGA recommends using fecal calprotectin >150 μg/g to rule in active inflammation and inform treatment adjustment in patients with moderate to severe symptoms 2, 3
  • Treatment should be initiated or adjusted based on the specific inflammatory bowel disease (IBD) type (Crohn's disease or ulcerative colitis) 1

Monitoring and Special Considerations

  • For patients with mild symptoms and fecal calprotectin >150 μg/g, endoscopic assessment is recommended before empiric treatment adjustment, as suggested by the AGA 2, 3
  • Repeat fecal calprotectin measurement is recommended 2-4 months after initiating or adjusting therapy to monitor response 1
  • Consider endoscopic assessment 6-12 months after treatment initiation to confirm mucosal healing 1
  • Fecal calprotectin may be elevated due to non-intestinal sources of infection or inflammation; stool testing for Clostridioides difficile and other enteric pathogens is important to help rule out other causes 3
  • The sensitivity of fecal calprotectin at a cutoff of 150 μg/g for detecting moderate to severe endoscopic inflammation is approximately 81% with a specificity of 72% 4
  • Biomarkers of inflammation have no role in dysplasia detection and surveillance 3

Management of Elevated Calprotectin

Diagnostic Approach

  • At a calprotectin cutoff of 250 μg/g, the specificity improves to 74% for detecting active disease, according to the American Gastroenterological Association 5
  • The false negative rate at <150 μg/g cutoff is 8.5% in patients with unknown endoscopic status, highlighting the importance of comprehensive assessment, as recommended by the American Gastroenterological Association 5

Monitoring and Treatment

  • The European Crohn’s and Colitis Organisation recommends repeat testing 2-4 months after initiating or adjusting therapy, with values <150 μg/g suggesting resolution of inflammation and no intervention needed, although this specific guideline is not directly cited, the concept is supported by 5
  • Persistently elevated calprotectin values (>150 μg/g) warrant repeat endoscopic assessment, as suggested by the American Gastroenterological Association, to guide ongoing management and adjust treatment as necessary 5